LB Pharmaceuticals announced that it’s moving forward on an IPO that will allow the biotech firm to raise the necessary cash to advance its oral schizophrenia candidate LB-102.

LB-102 is a methylated derivative of amisulpride, a second-generation antipsychotic drug that’s already approved in more than 50 countries, but not in the United States. The company expects to initiate Phase 3 trials in Q1, 2026, with topline data expected in 2027.

While the biotech IPO market hasn’t been particularly on fire this year, LB Pharmaceuticals expects to raise approximately $285 million. Here’s more: https://ir.lbpharma.us/press_releases/lb-pharmaceuticals-announces-pricing-of-its-upsized-initial-public-offering/

GE Healthcare announced it will be acquiring icometrix, a company that developed icobrain, an AI-powered brain imaging analysis for neurological disorders. The terms of the acquisition were not disclosed, but GE Healthcare expects to integrate icobrain, with its own MRI systems.

Icobrain includes the first FDA-cleared computer-aided detection and diagnosis solution for detecting and quantifying Amyloid Related Imaging Abnormalities (ARIA), the known side effects of amyloid targeting therapies. Check it out: https://www.businesswire.com/news/home/20250910522937/en/GE-HealthCare-announces-intent-to-acquire-icometrix-to-strengthen-neurology-portfolio-with-brain-MRI-assessment-solutions

Researchers announced that they uncovered a brain circuit in mice that acts as a “dial” for controlling the urge to eat sweets, fats, and salt. The circuit links the amygdala to the the bed nucleus of the stria terminalis (BNST), a region tied to feeding and reward.

According to a detailed study in the journal Cell, this discovery has the potential to treat overeating and undereating.  

Here’s what Dr. Charles Zuker, the study’s corresponding author, had to say…

“The relationship between something that stimulates the appetite, such as fat or sugar, and its capacity to drive us to consume it has been an open question in neuroscience. This work provides exciting new insights and identifies a brain center that orchestrates a unified control over consummatory behaviors.”

Here’s more: https://www.cell.com/cell/fulltext/S0092-8674(25)00976-6?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS0092867425009766%3Fshowall%3Dtrue

‍

Did you know that attention and focus abilities peak between the ages of 27 and 36?

According to researchers who analyzed neuroimaging studies spanning ages 5 to 85 to map the brain’s activity in cognitive control, there is an inverted U-shaped lifespan trajectory, with brain activity rising through adolescence, peaking between ages 27 and 36, and then gradually declining.

This pattern reflects peak cognitive efficiency in adulthood and highlights the importance of maintaining brain health later in life. Scientists say that these findings deepen our understanding of brain development and aging, which thereby offers a scientific foundation for age-tailored cognitive training and brain health strategies.  Check it out: https://www.sciencedirect.com/science/article/abs/pii/S2095927325008692?via%3Dihub